%0 Journal Article
%T MET Exon 14 Skipping Mutations in Non-small Cell Lung Cancer
%A Limei YIN
%A You LU
%J Öйú·Î°©ÔÓÖ¾
%D 2018
%R : 10.3779/j.issn.1009-3419.2018.07.09
%X Recently, targeted therapy has achieved great success in the treatment of non-small cell lung cancer (NSCLC) patients. Mesenchymal to epithelial transition factor (MET) is considered to be another important molecular target for NSCLC since epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK). Accumulating clinical trials and case reports have confirmed that MET inhibitors exhibited a potential prospect in treating patients with MET 14 exon skipping alterations, suggesting that MET 14 exon skipping mutation might be an effective biomarker for MET inhibitors, which remains to be confirmed by more clinical data. This review summarizes current research about the molecular mechanism, clinicopathological characterization, treatment strategies and drug resistance mechanisms of MET 14 exon skipping alterations in NSCLC.£¿
%K Lung neoplasms
%K MET
%K Tyrosine kinase inhibitors
%K Crizotinib
%K Targeted therapy
%U http://www.lungca.org/index.php?journal=01&page=article&op=view&path%5B%5D=10.3779%2Fj.issn.1009-3419.2018.07.09